Loading…
Fulgent Genetics, Inc. is projected to rise to $18.67 by 2027, a +13% move from its current price of $16.55. FLGT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $16.10 | $16.56 | $17.02 | +0.03% |
| Aug 4 | $15.93 | $16.56 | $17.22 | +0.07% |
| Aug 5 | $15.79 | $16.57 | $17.38 | +0.10% |
| Aug 6 | $15.68 | $16.57 | $17.51 | +0.13% |
| Aug 7 | $15.58 | $16.58 | $17.63 | +0.16% |
| Aug 8 | $15.50 | $16.58 | $17.74 | +0.20% |
| Aug 9 | $15.42 | $16.59 | $17.85 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.42 | $16.59 | $17.85 | +0.23% |
| Week 2 | $14.99 | $16.63 | $18.44 | +0.46% |
| Week 3 | $14.68 | $16.66 | $18.91 | +0.69% |
| Week 4 | $14.43 | $16.70 | $19.33 | +0.92% |
| Week 5 | $14.21 | $16.74 | $19.71 | +1.15% |
| Week 6 | $14.03 | $16.78 | $20.07 | +1.38% |
| Week 7 | $13.86 | $16.82 | $20.41 | +1.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fulgent Genetics, Inc. operates in the healthcare sector, delivering clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. On the clinical side, the company provides molecular diagnostic testing, genetic testing, and anatomic pathology laboratory tests and testing services across multiple specialties, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, as well as oncology tests and testing services.
Its therapeutic development solutions focus on developing drug candidates for treating cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company’s picture genetics platform includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients.
Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Fulgent Genetics, Inc. currently trades at $16.55 per share and has a market capitalization of $470.03M. The stock is ranked 2950 by market capitalization among global equities. The forecast landscape shows a path of gradual to strong upside over the coming years, with the average price rising from the mid-teens into the upper hundreds of dollars over the long horizon.
Notably, the 2030 average is $32.03 and the 2040 average is $67.97, with the 2050 average at $159.45, reflecting a broadly bullish longer-term trajectory. The forecast also features rising max prices and substantial ROI in later years, with 2030 ROI around 93.5%, 2040 around 310.7%, and 2050 around 863.5%. In the near term, the 2026 figure sits at an average of $16.55 with flat ROI, while sentiment remains NEUTRAL for the near horizon and turns BULLISH in the later years.
A major floor 19.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 29.2% above — a clean break opens room to run.
A major ceiling 39.0% above — clearing it would confirm fresh momentum.
Key FLGT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FLGT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.12 | Sell | $18.76 | Sell |
| MA 10 | $19.43 | Sell | $19.29 | Sell |
| MA 20 | $20.07 | Sell | $19.58 | Sell |
| MA 50 | $19.21 | Sell | $19.14 | Sell |
| MA 100 | $17.42 | Sell | $19.11 | Sell |
| MA 200 | $21.36 | Sell | $19.86 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 29.39 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -359.09 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.34 | Sell |
| ROC (12) | -21.23 | Sell |
| Bollinger %B (20,2) | -0.40 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | -0.56 | Sell |
| Ultimate (7,14,28) | 25.58 | Buy |
| Momentum (10) | -3.61 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 18.91 | Sell |
| ADX (14) | 16.81 | Neutral |
| ATR (14) | 0.56 | Info |
The 30-day technical picture shows a neutral stance. The RSI14 is 30, and the near-term moving averages place the price around the 50-day mark at $19.21 and the 200-day mark at $21.36. There is immediate technical support at $16.55 and resistance at $21.39.
The 30-day price range spans from a low of $13.79 to a high of $19.86, highlighting notable intramonth volatility. Annualized volatility is 50%, signaling meaningful upside and downside potential within a month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.79 | $16.55 | $22.42 | 0% | Neutral | |
| $14.87 | $18.67 | $24.79 | +13% | Neutral | |
| $16.70 | $21.57 | $29.75 | +30% | Bullish | |
| $19.28 | $25.50 | $36.23 | +54% | Bullish | |
| $23.72 | $32.03 | $46.64 | +94% | Bullish | |
| $25.69 | $35.36 | $52.61 | +114% | Bullish | |
| $26.33 | $36.88 | $55.95 | +123% | Bullish | |
| $28.12 | $40.05 | $61.83 | +142% | Bullish | |
| $28.71 | $41.54 | $65.17 | +151% | Bullish | |
| $32.06 | $47.09 | $74.99 | +185% | Bullish | |
| $43.23 | $67.97 | $115.22 | +311% | Bullish | |
| $90.15 | $159.45 | $295.99 | +863% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $13.79 | $16.55 | $20.52 | +0.00% |
| September 2026 | $14.35 | $16.98 | $20.68 | +2.62% |
| October 2026 | $14.31 | $17.05 | $20.98 | +0.39% |
| November 2026 | $14.79 | $17.73 | $22.00 | +3.97% |
| December 2026 | $14.87 | $17.92 | $22.42 | +1.08% |
Click any year to see its month-by-month FLGT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, FLGT is projected to trade between $13.79 and $22.42, averaging $16.55 — a potential gain of 0% from today's $16.55. Price action looks broadly range-bound.
Fulgent Genetics, Inc.'s 2027 outlook centres on $18.67, within a $14.87 to $24.79 range. That is up +13% on the projected 2026 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, FLGT could reach as high as $29.75, with a base case around $21.57 and support toward $16.70 — roughly +30% from $16.55. Momentum favours further upside here.
Expect FLGT to range from $19.28 to $36.23 through 2029. The $25.50 average target implies a +54% move from current prices. That is up +18% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The FLGT price prediction for 2030 points to an average of $32.03 (low $23.72, high $46.64) — a potential gain of +94% on today's $16.55. Momentum favours further upside here.
In 2031, FLGT is projected to trade between $25.69 and $52.61, averaging $35.36 — a potential gain of +114% from today's $16.55. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Fulgent Genetics, Inc.'s 2032 outlook centres on $36.88, within a $26.33 to $55.95 range. That is up +4% on the projected 2031 average. That marks a +123% change versus current levels. Momentum favours further upside here.
By 2033, FLGT could reach as high as $61.83, with a base case around $40.05 and support toward $28.12 — roughly +142% from $16.55. Buyers look set to stay in control over this stretch.
Expect FLGT to range from $28.71 to $65.17 through 2034. The $41.54 average target implies a +151% move from current prices. That is up +4% on the projected 2033 average. Momentum favours further upside here.
The FLGT price prediction for 2035 points to an average of $47.09 (low $32.06, high $74.99) — a potential gain of +185% on today's $16.55. Buyers look set to stay in control over this stretch.
In 2040, FLGT is projected to trade between $43.23 and $115.22, averaging $67.97 — a potential gain of +311% from today's $16.55. That is up +44% on the projected 2035 average. Momentum favours further upside here.
Fulgent Genetics, Inc.'s 2050 outlook centres on $159.45, within a $90.15 to $295.99 range. That is up +135% on the projected 2040 average. That marks a +863% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in FLGT today (≈ 60.422961 FLGT) could be worth
$9,634.66
+$8,634.66 (+863%) by 2050 · US Dollar
Based on the average projected FLGT price of $159.45 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FLGTwould be worth at today's price.
$1,000 invested in FLGT on Jul 31, 2025 (≈ 58.207217 FLGT) would be worth
$963.33
-$36.67 (-3.7%) today · 0.96× · US Dollar
Based on a FLGT entry price of $17.18 vs. today's $16.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.67 | $841.38 | -15.9% |
| 1 month ago | $20.82 | $794.91 | -20.5% |
| 3 months ago | $14.13 | $1,171.27 | +17.1% |
| 6 months ago | $26.12 | $633.61 | -36.6% |
| 1 year ago | $17.18 | $963.33 | -3.7% |
| All time (5.0y) ago | $100.46 | $164.74 | -83.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FLGT forecast.
Our base-case forecast reaches $33.00 around 2031.
Implied market cap at $33.00: $937.22M
The multi-year forecast points to a bullish trajectory, with the average price climbing from year to year and notable upside in later periods. By 2030, the average is forecast at $32.03 with a 93.5% ROI, and the sentiment is BULLISH. By 2040, the average is forecast at $67.97 with a 310.7% ROI, again BULLISH, followed by a 2050 average of $159.45 and an 863.5% ROI, remaining BULLISH.
The year-by-year increments show continued growth from 2027 onward, with 2027 at an average of $18.67 (12.8% ROI) and 2028 at $21.57 (30.4% ROI), then accelerating through 2029 at $25.50 (54.1% ROI) and beyond. These figures illustrate meaningful long-run upside, while noting that they are estimates and not guarantees. Investors should consider the period-specific risks and the inherent uncertainty in long-range forecasts.
Tap a question to reveal the answer.
In 2030 the forecasted average price is $32.03 with a minimum of $23.72 and a maximum of $46.64, and the expected ROI is 93.5% in a bullish outlook.
Forecasts show a bullish trajectory in the later years with ascending averages and rising ROI, including 2030 at 93.5% and 2050 at 863.5%, though the near term includes flat initial ROI and ongoing uncertainty; these are estimates, not guarantees.
The forecasted maximum in 2040 is $115.22, and by 2050 it is $295.99, indicating that reaching $100 is within the projected range by 2040 and well above it by 2050.
The current price is $16.55 per share and the market cap is $470.03M.
The 30-day range is from $13.79 to $19.86.
Fulgent Genetics, Inc. Community Discussion
0Share your Fulgent Genetics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.